FORM D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OME OMB NUMBER: Expires: Estimated average burde hours per response......



	SEC	USE ONLY	
Prefix	1	Serial	
	DATE	RECEIVED	
1	1		

Zudti ALE OF SECURITIES PURSUANT TO REGULATION D. SECTION 4(6), AND/OR WNIFORM LIMITED OFFERING EXEMPTION

FORM D

Name of Offering (check if this is an amendment and name has changed, and indicate change.)

A. BASIC IDENTIFICATION DATA 1. Enter the information requested about the issuer Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Novobiotic Pharmaceuticals, LLC Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics.	Series B Preferred Shares		<i>;</i>
A. BASIC IDENTIFICATION DATA 1. Enter the information requested about the issuer Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Novobiotic Pharmaceuticals, LLC Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed business trust limited partnership, to be formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 Actual contact in the information indicate change.) FHOMSON FHOMSON	Filing Under (Check box(es) that apply):	Rule 504 □ Rule 505 ■ Rule 506 □ Section	4(6) □ ULOE
Name of Issuer (□ check if this is an amendment and name has changed, and indicate change.) Novobiotic Pharmaceuticals, LLC Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization □ corporation □ limited partnership, already formed □ business trust □ limited partnership, to be formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 ■ Actual □ Estimated	Type of Filing: ■ New Filing □ Amendment		/PROCECCE
Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Novobiotic Pharmaceuticals, LLC Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 Actual city State, Zip Code) Telephone Number (Including Area Code)		A. BASIC IDENTIFICATION DATA	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.) Novobiotic Pharmaceuticals, LLC Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 Actual city State, Zip Code) Telephone Number (Including Area Code)	1. Enter the information requested about the issuer		OCT 0 3 2006
Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed business trust other (please specify): Limited Liability Company	Name of Issuer (check if this is an amendment and t	name has changed, and indicate change.)	
Address of Executive Offices (Number and Street, City, State, Zip Code) 767C Concord Avenue, Cambridge, MA 02138 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed business trust other (please specify): Limited Liability Company	Novobiotic Pharmaceuticals, LLC		FINANCIAL
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation limited partnership, already formed business trust limited partnership, to be formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 Telephone Number (Including Area Code) Telephone Number (Including Area Code) Telephone Number (Including Area Code)	Address of Executive Offices (Number and Stree	et, City, State, Zip Code)	
Brief Description of Business: pharmaceutical company focused on the development of novel antibiotics. Type of Business Organization corporation business trust business trust Month Year Actual or Estimated Date of Incorporation or Organization 10 03 Brief Description of Business: ### Other (please specify): Limited Liability Company #### Other (please specify): Limited Liability Company ###################################	767C Concord Avenue, Cambridge, MA 02138		617-864-2880
Type of Business Organization corporation business trust Month Year Actual or Estimated Date of Incorporation or Organization Type of Business Organization business trust Actual or Estimated Date of Incorporation or Organization Type of Business Organization business Organization business Organization business trust Dimited partnership, to be formed Month Year Actual Date of Incorporation or Organization Dimited partnership, to be formed	Address of Principal Business Operations (if different from Executive Offices)	(Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
Type of Business Organization corporation business trust Month Year Actual or Estimated Date of Incorporation or Organization I limited partnership, already formed Month Year Actual Date of Incorporation or Organization Actual Date of Incorporation or Organization Dimited partnership, already formed Description or Organization One of Incorporation or Organization Dimited partnership, already formed Description Other (please specify): Limited Liability Company Dimited Date of Incorporation or Organization One	Brief Description of Business:		
□ corporation □ limited partnership, already formed □ business trust □ limited partnership, to be formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 ■ Actual □ Estimated	pharmaceutical company focused on the developme	ent of novel antibiotics.	
□ business trust □ limited partnership, to be formed Month Year Actual or Estimated Date of Incorporation or Organization 10 03 ■ Actual □ Estimated	Type of Business Organization		
Month Year Actual or Estimated Date of Incorporation or Organization 10 03 ■ Actual □ Estimated	□ corporation	☐ limited partnership, already formed	■ other (please specify): Limited Liability Company
Actual or Estimated Date of Incorporation or Organization 10 03 Actual Estimated	□ business trust		
		Month Year	
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for State:			Estimated
CN for Canada; FN for other foreign jurisdiction) MA	Jurisdiction of Incorporation or Organization: (Enter to		МА
	GENERAL INSTRUCTIONS	on for canada, in for other foreign jurisdiction)	17 A.C. B.

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file apprapriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice

		A. BASIC IDENTI	FICATION DATA		
 Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer; Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. 					
Check Box(es) that Apply:	□ Promoter	□ Beneficial Owner	☐ Executive Officer	☐ Director	■ General and/or Managing Partner
Full Name (Last name first, if individual)					
Salaman Anam T					
Salzman, Aram T. Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)		
2 35	(, , umov, umu s	, 0.1,, 2, 2	,		
c/o Novobiotic Pharmaceuticals, LLC, 7	67C Concord A	venue, Cambridge, MA	02138		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	■ General and/or Managing Partner
Full Name (Last name first, if individual)					
Lewis, Kim					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)	. , , , ,	
c/o Novobiotic Pharmaceuticals, LLC, 7					
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	■ General and/or Managing Partner
Full Name (Last name first, if individual)					
Epstein, Slava S.					
Business or Residence Address	(Number and St	reet, City, State, Zip Cod	e)	, -	and the second s
c/o Novobiotic Pharmaceuticals, LLC, 7		· · · · · · · · · · · · · · · · · · ·			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	□Executive Officer	☐ Director	■ General and/or Managing Partner
Full Name (Last name first, if individual)					
Keegan, Harry P., III					
Business or Residence Address	(Number and St	reet, City, State, Zip Cod	e)		
a/a Navahiatia Phanasautiaala III C. 7	67C Camanud A		03130		
c/o Novobiotic Pharmaceuticals, LLC, 7 Check Box(es) that Apply:	□ Promoter	Beneficial Owner □ Beneficial Owner	□ Executive Officer	□ Director	■ General and/or Managing Partner
Full Name (Last name first, if individual)	- Fiolilotei	D Belleticial Owliel	Li Executive Officer	□ Director	General and/or Wanaging Farther
t an itame (East hame inst, it matridual)					
Kelley, Thomas M.					
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	le)		
c/o Novobiotic Pharmaceuticals, LLC, 7	67C Cancard A	venue Cambridge MA	02138		
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Mendelson Investments G.P.	01 1 16	0: 0: 7: 0			
Business or Residence Address	(Number and S	treet, City, State, Zip Coo	1e)		
320 Central Park West, Apt. 16B, New	York, NY 10025	5			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)			_		<u> </u>
~ ··· ~ ·					
Zouikin, Tania	(A)		1.\		
Business or Residence Address	(Number and	Street, City, State, Zip Co	de)		
20 Rowes Wharf #410, Boston, MA 021	10				
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)				*****	
District 1					
Biobiotic, Inc. Business or Residence Address	(Number and 6	Street, City, State, Zip Co	da)		
Dusiness of Residence Address	(Tunnoel and l	moon, only, branc, Zip Co	۵۷,		

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

13 Templeton Parkway, Watertown, MA 02472

	B. INFORMATION ABOUT OFFERING		
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?		•
	Answer also in Appendix, Column 2, if filing under ULOE.		
2.	What is the minimum investment that will be accepted from any individual?	\$ <u>n/a</u>	N1-
3. !	Does the offering permit joint ownership of a single unit?	Yes	No
	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or	•	
: :	similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full N None.	lame (Last name first, if individual)		
Busin	ess or Residence Address (Number and Street, City, State, Zip Code)		
Name	of Associated Broker or Dealer		
States	in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [Al _ [IL _ [M _ [R	_] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] IT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full n	ame (Last name first, if individual)		
Busin	ess or Residence Address (Number and Street, City, State, Zip Code)		
Name	of Associated Broker or Dealer		· · · · · · · · · · · · · · · · · · ·
States	in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [A] _ [II _ [M _ [R	_] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] IT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full N	Vame (Last name first, if individual)		
Busin	less or Residence Address (Number and Street, City, State, Zip Code)		
Name	of Associated Broker or Dealer	· · · · · · · · · · · · · · · · · · ·	
States	s in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
_ [A _ [II _ [N _ [R	L] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] 4T] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS $\,$

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box pand indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Already Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$ <u>1,099,998</u>	\$1,028,106
	□ Common ■ Preferred		
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$	\$
	Other (Specify)	\$	\$
	Total	\$_1,099,998	S <u>1,028,106</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	23	\$ <u>1,028,106</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		Ψ
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question I. Type of offering	Type of Security	Dollar Amount Sold
	Rule 505		
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$
	Printing and Engraving Costs.	0	\$
	Legal Fees	•	\$20,000
	Accounting Fees	О	\$
	Engineering Fees	D	\$
	Sales Commissions (specify finders' fees separately)	0	\$
	Other Expenses (identify)		\$
	Total	•	\$ 20,000

b. Enter the difference between the aggregate offering price given in response to Part C – 1 and total expenses furnished in response to Part C – Question 4.a. This difference is the "adjusted gross proceeds to the issuer."			:	1.079.998
5. Indicate below the amount of the adjusted gross proceeds to the issuer used or proposed to for each of the purposes shown. If the amount for any purpose is not known, furnish an earn check the box to the left of the estimate. The total of the payments listed must equal to adjusted gross proceeds to the issuer set forth in response to Part C - Question 4.b above.	stimate			
		Payments to Officers, Directors, & Affiliates		Payments To Others
Salaries and fees	0	\$		\$
Purchase of real estate	0	\$		\$
Purchase, rental or leasing and installation of machinery and equipment		\$		S
Construction or leasing of plant buildings and facilities	0	\$	۵	\$
Acquisition of other business (including the value of securities involved in this offering that may be used in exchange for the assets or securities of another issuer pursuant to a merger)		•	_	•
Repayment of indebtedness	0	s	0	ς
Working capital		s	-	\$_1,079,998
Other (specify):	0	<u></u>		\$ <u>1,072,720</u>
Ond (specify).	. 0	J	o.	Ø <u> </u>
		\$		
	0		0	3
Column Totals		\$ <u> </u>	•	\$ <u>1,079,998</u>
Total Payments Listed (column totals added)		■ \$ <u>1.</u>	079,998	_
D. FEDERAL SIGNATU	RE			
The issuer has duly caused this notice to be signed by the undersigned duly authorized person. It am undertaking by the issuer to furnish to the U.S. Securities and Exchange Commission, upon whom-accredited investor pursuant to paragraph (b)(2) of Rule 502.				
Issuer (Print or Type) Signature		Date		
Novobiotic Pharmaceuticals, LLC	<u> </u>	September 20, 2006		
Name of Signer (Print or Type) Title of Signer (Print or Type))			
Aram T. Salzman President and Chief Executive Office	e r			
				

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)